Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models

Current Opinion in Virology

Volumn 13, Issue , 2015, Pages 61-66

  Tang, William W ^a   Grewal, Rajvir ^a   Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; INTERFERON RECEPTOR; VIRUS ANTIBODY;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN BINDING; ARTICLE; BLOOD VESSEL PERMEABILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEX FORMATION; CROSS REACTION; DENGUE; DISEASE SEVERITY; MEDIATOR RELEASE; MEMORY T LYMPHOCYTE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; SECONDARY INFECTION; T LYMPHOCYTE; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION; ANIMAL; DENGUE VIRUS; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, INTERFERON; T-LYMPHOCYTES;

EID: 84931262987     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2015.04.007     Document Type: Review

References (55)

1. S.B. Halstead Dengue Lancet 370 2007 1644 1652
2. S. Bhatt, P.W. Gething, O.J. Brady, J.P. Messina, A.W. Farlow, C.L. Moyes, J.M. Drake, J.S. Brownstein, A.G. Hoen, O. Sankoh, M.F. Myers, D.B. George, T. Jaenisch, G.R. Wint, C.P. Simmons, T.W. Scott, J.J. Farrar, and S.I. Hay The global distribution and burden of dengue Nature 496 2013 504 507
3. A. Sabchareon, D. Wallace, C. Sirivichayakul, K. Limkittikul, P. Chanthavanich, S. Suvannadabba, V. Jiwariyavej, W. Dulyachai, K. Pengsaa, T.A. Wartel, A. Moureau, M. Saville, A. Bouckenooghe, S. Viviani, N.G. Tornieporth, and J. Lang Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial Lancet 380 2012 1559 1567
4. M.R. Capeding, N.H. Tran, S.R. Hadinegoro, H.I. Ismail, T. Chotpitayasunondh, M.N. Chua, C.Q. Luong, K. Rusmil, D.N. Wirawan, R. Nallusamy, P. Pitisuttithum, U. Thisyakorn, I.K. Yoon, D. van der Vliet, E. Langevin, T. Laot, Y. Hutagalung, C. Frago, M. Boaz, T.A. Wartel, N.G. Tornieporth, M. Saville, A. Bouckenooghe, and C.Y.D.S. Group Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial Lancet 384 2014 1358 1365
5. L. Villar, G.H. Dayan, J.L. Arredondo-Garcia, D.M. Rivera, R. Cunha, C. Deseda, H. Reynales, M.S. Costa, J.O. Morales-Ramirez, G. Carrasquilla, L.C. Rey, R. Dietze, K. Luz, E. Rivas, M.C. Montoya, M.C. Supelano, B. Zambrano, E. Langevin, M. Boaz, N. Tornieporth, M. Saville, F. Noriega for the CYD15 Study Group Efficacy of a tetravalent dengue vaccine in children in Latin America N Engl J Med 372 2014 113 123
6. R. Tapia-Conyer, M. Betancourt-Cravioto, and J. Mendez-Galvan Dengue: an escalating public health problem in Latin America Paediatr Int Child Health 32 Suppl. 1 2012 14 17
7. A. Balmaseda, S.N. Hammond, L. Perez, Y. Tellez, S.I. Saborio, J.C. Mercado, R. Cuadra, J. Rocha, M.A. Perez, S. Silva, C. Rocha, and E. Harris Serotype-specific differences in clinical manifestations of dengue Am J Trop Med Hyg 74 2006 449 456
8. R.V. Gibbons, and D.W. Vaughn Dengue: an escalating problem BMJ 324 2002 1563 1566
9. D.P. Webster, J. Farrar, and S. Rowland-Jones Progress towards a dengue vaccine Lancet Infect Dis 9 2009 678 687
10. PAHO/WHO Number of Reported Cases of Dengue and Severe Dengue (SD) in the Americas, by Country - January 05, 2015 (EW 51) 2014
11. S.B. Halstead, and E.J. O'Rourke Antibody-enhanced dengue virus infection in primate leukocytes Nature 265 1977 739 741
12. A.L. Rothman Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms Nat Rev Immunol 11 2011 532 543
13. J. Mongkolsapaya, W. Dejnirattisai, X.N. Xu, S. Vasanawathana, N. Tangthawornchaikul, A. Chairunsri, S. Sawasdivorn, T. Duangchinda, T. Dong, S. Rowland-Jones, P.T. Yenchitsomanus, A. McMichael, P. Malasit, and G. Screaton Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever Nat Med 9 2003 921 927
14. W.B. Messer, U.T. Vitarana, K. Sivananthan, J. Elvtigala, L.D. Preethimala, R. Ramesh, N. Withana, D.J. Gubler, and A.M. De Silva Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever Am J Trop Med Hyg 66 2002 765 773
15. R. Rico-Hesse, L.M. Harrison, R.A. Salas, D. Tovar, A. Nisalak, C. Ramos, J. Boshell, M.T. de Mesa, R.M. Nogueira, and A.T. da Rosa Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas Virology 230 1997 244 251
16. R. Cologna, P.M. Armstrong, and R. Rico-Hesse Selection for virulent dengue viruses occurs in humans and mosquitoes J Virol 79 2005 853 859
17. R. Rico-Hesse Dengue virus evolution and virulence models Clin Infect Dis 44 2007 1462 1466
18. D.M. Watts, K.R. Porter, P. Putvatana, B. Vasquez, C. Calampa, C.G. Hayes, and S.B. Halstead Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever Lancet 354 1999 1431 1434
19. L.E. Yauch, and S. Shresta Mouse models of dengue virus infection and disease Antiviral Res 80 2008 87 93
20. S. Aguirre, A.M. Maestre, S. Pagni, J.R. Patel, T. Savage, D. Gutman, K. Maringer, D. Bernal-Rubio, R.S. Shabman, V. Simon, J.R. Rodriguez-Madoz, L.C. Mulder, G.N. Barber, and A. Fernandez-Sesma DENV inhibits type I IFN production in infected cells by cleaving human STING PLoS Pathog 8 2012 e1002934
21. J. Ashour, J. Morrison, M. Laurent-Rolle, A. Belicha-Villanueva, C.R. Plumlee, D. Bernal-Rubio, K.L. Williams, E. Harris, A. Fernandez-Sesma, C. Schindler, and A. Garcia-Sastre Mouse STAT2 restricts early dengue virus replication Cell Host Microbe 8 2010 410 421
22. C.Y. Yu, T.H. Chang, J.J. Liang, R.L. Chiang, Y.L. Lee, C.L. Liao, and Y.L. Lin Dengue virus targets the adaptor protein MITA to subvert host innate immunity PLoS Pathog 8 2012 e1002780
23. S.J. Balsitis, K.L. Williams, R. Lachica, D. Flores, J.L. Kyle, E. Mehlhop, S. Johnson, M.S. Diamond, P.R. Beatty, and E. Harris Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification PLoS Pathog 6 2010 e1000790
24. S. Shresta, K.L. Sharar, D.M. Prigozhin, P.R. Beatty, and E. Harris Murine model for dengue virus-induced lethal disease with increased vascular permeability J Virol 80 2006 10208 10217
25. R.M. Zellweger, T.R. Prestwood, and S. Shresta Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease Cell Host Microbe 7 2010 128 139
26. S.T. Perry, T.R. Prestwood, S.M. Lada, C.A. Benedict, and S. Shresta Cardif-mediated signaling controls the initial innate response to dengue virus in vivo J Virol 83 2009 8276 8281
27. S. Orozco, M.A. Schmid, P. Parameswaran, R. Lachica, M.R. Henn, R. Beatty, and E. Harris Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor J Gen Virol 93 2012 2152 2157
28. H. Makhluf, M.D. Buck, K. King, S.T. Perry, M.R. Henn, and S. Shresta Tracking the evolution of dengue virus strains D2S10 and D2S20 by 454 pyrosequencing PLoS One 8 2013 e54220
29. D. Weiskopf, M.A. Angelo, J. Sidney, B. Peters, S. Shresta, and A. Sette Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection J Virol 88 2014 11383 11394
30. D. Weiskopf, L.E. Yauch, M.A. Angelo, D.V. John, J.A. Greenbaum, J. Sidney, R.V. Kolla, A.D. De Silva, A.M. de Silva, H. Grey, B. Peters, S. Shresta, and A. Sette Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design J Immunol 187 2011 4268 4279
31. R. Zust, Y.X. Toh, I. Valdes, D. Cerny, J. Heinrich, L. Hermida, E. Marcos, G. Guillen, U. Kalinke, P.Y. Shi, and K. Fink Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines J Virol 88 2014 7276 7285
32. M.S. Diamond, M. Kinder, H. Matsushita, M. Mashayekhi, G.P. Dunn, J.M. Archambault, H. Lee, C.D. Arthur, J.M. White, U. Kalinke, K.M. Murphy, and R.D. Schreiber Type I interferon is selectively required by dendritic cells for immune rejection of tumors J Exp Med 208 2011 1989 2003
33. T.R. Prestwood, M.M. May, E.M. Plummer, M.M. Morar, L.E. Yauch, and S. Shresta Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice J Virol 86 2012 12138 12147
34. M.A. Schmid, and E. Harris Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication PLoS Pathog 10 2014 e1004541
35. M. Beltramello, K.L. Williams, C.P. Simmons, A. Macagno, L. Simonelli, N.T. Quyen, S. Sukupolvi-Petty, E. Navarro-Sanchez, P.R. Young, A.M. de Silva, F.A. Rey, L. Varani, S.S. Whitehead, M.S. Diamond, E. Harris, A. Lanzavecchia, and F. Sallusto The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity Cell Host Microbe 8 2010 271 283
36. D.R. Burton Antibodies, viruses and vaccines Nat Rev Immunol 2 2002 706 713
37. T.C. Pierson, and M.S. Diamond Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection Expert Rev Mol Med 10 2008 e12
38. R. de Alwis, K.L. Williams, M.A. Schmid, C.Y. Lai, B. Patel, S.A. Smith, J.E. Crowe, W.K. Wang, E. Harris, and A.M. de Silva Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera PLoS Pathog 10 2014 e1004386
39. S.A. Smith, A.R. de Alwis, N. Kose, E. Harris, K.D. Ibarra, K.M. Kahle, J.M. Pfaff, X. Xiang, B.J. Doranz, A.M. de Silva, S.K. Austin, S. Sukupolvi-Petty, M.S. Diamond, and J.E. Crowe Jr. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein mBio 4 2013 e00873 e00913
40. K.L. Williams, S. Sukupolvi-Petty, M. Beltramello, S. Johnson, F. Sallusto, A. Lanzavecchia, M.S. Diamond, and E. Harris Therapeutic efficacy of antibodies lacking Fcgamma receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies PLoS Pathog 9 2013 e1003157
41. S. Sukupolvi-Petty, S.K. Austin, M. Engle, J.D. Brien, K.A. Dowd, K.L. Williams, S. Johnson, R. Rico-Hesse, E. Harris, T.C. Pierson, D.H. Fremont, and M.S. Diamond Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2 J Virol 84 2010 9227 9239
42. B. Shrestha, J.D. Brien, S. Sukupolvi-Petty, S.K. Austin, M.A. Edeling, T. Kim, K.M. O'Brien, C.A. Nelson, S. Johnson, D.H. Fremont, and M.S. Diamond The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1 PLoS Pathog 6 2010 e1000823
43. J.K. Ng, S.L. Zhang, H.C. Tan, B. Yan, J.M. Martinez, W.Y. Tan, J.H. Lam, G.K. Tan, E.E. Ooi, and S. Alonso First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies PLoS Pathog 10 2014 e1004031
44. R.M. Zellweger, R. Miller, W.E. Eddy, L.J. White, R.E. Johnston, and S. Shresta Role of humoral versus cellular responses induced by a protective dengue vaccine candidate PLoS Pathog 9 2013 e1003723
45. A.J. Johnson, and J.T. Roehrig New mouse model for dengue virus vaccine testing J Virol 73 1999 783 786
46. M.M. Mangada, and A.L. Rothman Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes J Immunol 175 2005 2676 2683
47. J. Mongkolsapaya, T. Duangchinda, W. Dejnirattisai, S. Vasanawathana, P. Avirutnan, A. Jairungsri, N. Khemnu, N. Tangthawornchaikul, P. Chotiyarnwong, K. Sae-Jang, M. Koch, Y. Jones, A. McMichael, X. Xu, P. Malasit, and G. Screaton T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol 176 2006 3821 3829
48. B.R. Murphy, and S.S. Whitehead Immune response to dengue virus and prospects for a vaccine Annu Rev Immunol 29 2011 587 619
49. L.E. Yauch, R.M. Zellweger, M.F. Kotturi, A. Qutubuddin, J. Sidney, B. Peters, T.R. Prestwood, A. Sette, and S. Shresta A protective role for dengue virus-specific CD8+ T cells J Immunol 182 2009 4865 4873
50. L.E. Yauch, T.R. Prestwood, M.M. May, M.M. Morar, R.M. Zellweger, B. Peters, A. Sette, and S. Shresta CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination J Immunol 185 2010 5405 5416
51. T.R. Prestwood, M.M. Morar, R.M. Zellweger, R. Miller, M.M. May, L.E. Yauch, S.M. Lada, and S. Shresta Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-alpha/beta receptor-deficient mice J Virol 86 2012 12561 12570
52. R.M. Zellweger, W.E. Eddy, W.W. Tang, R. Miller, and S. Shresta CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice J Immunol 193 2014 4117 4124
53. S. Zompi, B.H. Santich, P.R. Beatty, and E. Harris Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells J Immunol 188 2012 404 416
54. D. Weiskopf, M.A. Angelo, E.L. de Azeredo, J. Sidney, J.A. Greenbaum, A.N. Fernando, A. Broadwater, R.V. Kolla, A.D. De Silva, A.M. de Silva, K.A. Mattia, B.J. Doranz, H.M. Grey, S. Shresta, B. Peters, and A. Sette Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells Proc Natl Acad Sci U S A 110 2013 E2046 E2053
55. C.P. Simmons, T. Dong, N.V. Chau, N.T. Dung, T.N. Chau, T.T. Thao le, N.T. Dung, T.T. Hien, S. Rowland-Jones, and J. Farrar Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections J Virol 79 2005 5665 5675